Arphion is a company established to develop noninvasive products that will be used to diagnose, prevent, and treat head and neck and other cancers. 41,000 people are diagnosed with head and neck cancer (HNC) every year in the United States, with 8,000 deaths. Arphion is exploring the relationship between certain oral bacteria and tobacco usage. Based on academic findings that certain oral bacteria increase with tobacco usage (and tobacco, in turn, is known to be associated with increased cancers in the head and neck), the company is investigating developing tests and therapies to assist with HNC.
